 |
COVID19 Road to a vaccineThe year 2020 has seen the emergence of the SARS-CoV-2 virus (COVID19), a unique and potentially devastating virus, with no known prevention or treatment. This new SARS-CoV-2 virus has shown to not only have significant international health... Author: MVEC
The year 2020 has seen the emergence of the SARS-CoV-2 virus (COVID19), a unique and potentially devastating virus, with no known prevention or treatment. This new SARS-CoV-2 virus has shown to not only have significant international health implications, but also immense psychological and economic impacts. Associate Professor Nigel Crawford, a vaccinologist and consultant paediatrician at the Murdoch Childrens Research Institute (MCRI) & Royal Childrens Hospital (RCH), Melbourne, will delve into the global pursuit of a safe and effective vaccine to prevent COVID19. This is all occurring at pandemic speed and MVECs new podcast will explore this complicated and multi-faceted process through interviews with a variety of national and international vaccine experts. Language: en Genres: Health & Fitness, Medicine Contact email: Get it Feed URL: Get it iTunes ID: Get it |
Listen Now...
The final episode of COVID19 Road to a vaccine with Professor Walter Orenstein
Sunday, 22 November, 2020
In the final episode of this podcast series our host, Associate Professor Nigel Crawford, speaks with Professor Walter Orenstein. Dr Orenstein is a Professor of Medicine, Epidemiology, Global Health and Paediatrics at Emory University; Associate Director of the Emory Vaccine Center and the Director of Emory Vaccine Policy and Development. An expert in vaccinology, Dr Orenstein has worked at the US Centers for Disease Control and Prevention, Director of the United States Immunisation Program and is a current member of several WHO groups. Further to this he is the co-editor of the vaccine textbook, Plotkin’s Vaccines, 7th edition. In this episode they discuss:•Lessons that can be learnt from Plotkin’s Vaccines in the setting of the SARS-CoV-2 pandemic and development of vaccines•Recent press releases showing promising early results from two mRNA COVID-19 vaccine candidates developed by Pfizer/BioNTech and Moderna •The critical role of ongoing monitoring for safety and effectiveness of vaccines once they are in use•The likely highest priority groups when vaccines do become available•The role of children in SARS-CoV-2 transmission and whether or not they need to be vaccinated•The importance of a correlate of protection in SARS-CoV-2 vaccines•The need to monitor for vaccine associated enhanced disease (VAED)•The importance of immunisation providers supporting reports of adverse events following immunisation (AEFI)•The importance of communication in supporting vaccine acceptance and uptake•Key next steps on the road to a COVID-19 vaccine: a better understanding of how many doses are required and when, a prioritisation process so the vaccines can be used most effectively (with a clear allocation system); and communicating to the public that social distancing and wearing a mask will be ongoing for some time as a level of normality won’t be reached immediately, even with the exciting new efficacious COVID-19 vaccines Links: Plotkin’s Vaccines, 7th edhttps://www.elsevier.com/books/T/A/9780323357616 Pfizer/BioNTech conclude phase 3 study of COVID-19 vaccine candidate, meeting all primary efficacy endpointshttps://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine Moderna’s COVID-19 vaccine candidate meets its primary efficacy endpoint in the first interim analysis of the phase 3 COVE study https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy
